Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Policy / Regulatory

National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs

Fineline Cube Nov 28, 2024

The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for...

Company Deals

Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs

Fineline Cube Nov 28, 2024

Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs)...

Policy / Regulatory

China’s NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030

Fineline Cube Nov 28, 2024

The National Health Commission (NHC) has released a notification aimed at enhancing the continuity of...

Company Drug

Jiangsu Kanion Pharmaceutical Secures NMPA Approvals for KYHY2302 and KYHY2303

Fineline Cube Nov 28, 2024

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals...

Policy / Regulatory

NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs

Fineline Cube Nov 28, 2024

The National Healthcare Security Administration (NHSA) has issued the “Guidelines for Risk Management of In-Shortage...

Company Drug

BeiGene’s Tevimbra Receives EC Approval for First-Line ESCC and G/GEJ Adenocarcinoma Treatments

Fineline Cube Nov 28, 2024

China-based biotech company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has received a marketing...

Company Drug

Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Cervical Muscle Tone Disorders

Fineline Cube Nov 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Drug

Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE

Fineline Cube Nov 28, 2024

Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing...

Company Drug

Hansoh Pharmaceutical’s Ameile Receives NMPA Review for Fifth Indication in NSCLC Treatment

Fineline Cube Nov 28, 2024

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that its fifth indication filing...

Company Drug

China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005

Fineline Cube Nov 28, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...

Company Medical Device

Genesis RMN Robotic Magnetic Navigation System Approved by China’s NMPA

Fineline Cube Nov 28, 2024

The Genesis RMN cardiac electrophysiological robot magnetic navigation system, represented in China by Shanghai Microport...

Company Drug

GSK plc Receives EC Approval for Single-Vial Menveo Vaccine for Meningococcal Disease

Fineline Cube Nov 28, 2024

GSK plc (NYSE: GSK) has announced that it has received marketing approval from the European...

Company Deals

TenNor Therapeutics Partners with Grand Life Sciences for Rifasutenizol Commercialization in China

Fineline Cube Nov 28, 2024

China-based TenNor Therapeutics has entered into an exclusive commercialization cooperation agreement with compatriot firm Grand...

Company Drug

Immunochina Pharmaceuticals’ IM19 CAR-T Therapy Accepted for Review by NMPA

Fineline Cube Nov 28, 2024

Beijing-based biotech company Immunochina Pharmaceuticals has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment

Fineline Cube Nov 28, 2024

China-based Thederma has announced that its TAP-1503 cream has been granted approval by the National...

Company Drug

Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer

Fineline Cube Nov 28, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced that it has received marketing approval from...

Company

Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore

Fineline Cube Nov 28, 2024

Global healthcare company Sanofi (NASDAQ: SNY) has inaugurated Modulus, its state-of-the-art manufacturing facility in Singapore....

Company Drug

Chia Tai Tianqing’s Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment

Fineline Cube Nov 27, 2024

China-based Chia Tai Tianqing has announced that the National Medical Products Administration (NMPA) has granted...

Company Drug

Sichuan Kelun-Biotech’s SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer

Fineline Cube Nov 27, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a China-based biopharmaceutical company, has received market approval...

Policy / Regulatory

NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030

Fineline Cube Nov 27, 2024

The National Healthcare Commission (NHC) has issued the “Guiding Opinions on Further Promoting Mutual Recognition...

Posts pagination

1 … 303 304 305 … 711

Recent updates

  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.